Mark W. Rixon

2.2k citations

25 papers · 1.1k indexed · 1 hit paper · h-index 13

Immunology top 5%
- T-cell and B-cell Immunology 10
- Immune Cell Function and Interaction 7
- Immunodeficiency and Autoimmune Disorders 3
Radiology, Nuclear Medicine and Imaging top 5%
- Monoclonal and Polyclonal Antibodies Research 8
Immunology and Allergy top 10%
Hematology top 10%
Genetics top 10%
- Hemoglobinopathies and Related Disorders 3
Pulmonary and Respiratory Medicine
- Blood properties and coagulation 4
Molecular Biology
- Glycosylation and Glycoproteins Research 3
- RNA modifications and cancer 3

Co-authors: Dominic W. Chung Earl W. Davie Stacey R. Dillon Sherri Mudri Jane A. Gross Harald S. Haugen Susan McMillen Kim Waggie
Cited by: Immunology Radiology, Nuclear Medicine and Imaging Immunology and Allergy
Journals: Biochemistry (4 papers)The Journal of Immunology (2 papers)Proceedings of the National Academy of Sciences (2 papers)
Partner nations: United States Germany South Africa

In The Last Decade

Mark W. Rixon

23 papers receiving 1.1k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Mark W. Rixon

Since Specialization

Citations

This map shows the geographic impact of Mark W. Rixon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Rixon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Rixon more than expected).

Fields of papers citing papers by Mark W. Rixon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Rixon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Rixon. The network helps show where Mark W. Rixon may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark W. Rixon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark W. Rixon Line = papers co-authored together Mark W. Rixon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Non‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101) Arthritis & Rheumatology ·Stacey R. Dillon,Lawrence S. Evans,Katherine E. Lewis,Salomé Álvarez Rodríguez,Tiffany C. Blair,Sherri Mudri,Miklas Schulz,Steven D. Levin,Janhavi Bhandari,Leena Bardwaj,Martin F. Wolfson,Pamela M. Holland,Mark W. Rixon,Stanford L. Peng	2023	7
2	The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity Nature Communications ·Mark Maurer,Katherine E. Lewis,Joseph L. Kuijper,S.J. Roest,Chelsea J. Gudgeon,Siddarth Chandrasekaran,Sherri Mudri,Miklas Schulz,Catherine C Hattie,Martin F. Wolfson,Mark W. Rixon,Ryan Swanson,Stacey R. Dillon,Steven D. Levin,寛小松,Masato Akutsu,Derek T. Logan,Björn Walse,Kristine M. Swiderek,Stanford L. Peng	2022	20
3	OP0039 ALPN-303, AN ENHANCED, POTENT DUAL BAFF/APRIL ANTAGONIST ENGINEERED BY DIRECTED EVOLUTION FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER B CELL-RELATED AUTOIMMUNE DISEASES Annals of the Rheumatic Diseases ·Stacey R. Dillon,Lawrence S. Evans,Katherine E. Lewis,D.F.Ellison Nash,Mark W. Rixon,Joseph L. Kuijper,Daniel Demonte,Janhavi Bhandari,Steven D. Levin,Miklas Schulz,Sherri Mudri,Susan Bort,Mutiu Adesina Adeleye,بلعباس عبدالوهاب,Hamsal Hamsal,Chelsea J. Gudgeon,Blau Souza,Martin F. Wolfson,Jan Hillson,Stanford L. Peng	2021	3
4	Novel Immunomodulatory Proteins Generated via Directed Evolution of Variant IgSF Domains Frontiers in Immunology ·Steven D. Levin,Lawrence S. Evans,Susan Bort,Erika Rickel,Katherine E. Lewis,Reetta Ahonen,Joe Hoover,Hilton C. Braithwaite,David La,Martin F. Wolfson,Mark W. Rixon,Stacey R. Dillon,M. G. Kornacker,Ryan Swanson,Stanford L. Peng	2020	9
5	P156 ALPN-101, A FIRST-IN-CLASS DUAL ICOS/CD28 ANTAGONIST, DEMONSTRATES EFFICACY IN PATIENT-DERIVED PBMC IN VITRO AND IN AN IN VIVO T CELL TRANSFER MODEL OF CHRONIC INFLAMMATORY BOWEL DISEASE (IBD) Gastroenterology ·Kristine M. Swiderek,Stacey R. Dillon,John L. Moore,Susan Bort,Sherri Mudri,Katherine E. Lewis,Mark W. Rixon,Janhavi Bhandari,Stanford L. Peng	2020	1
6	P156 ALPN-101, A FIRST-IN-CLASS DUAL ICOS/CD28 ANTAGONIST, DEMONSTRATES EFFICACY IN PATIENT-DERIVED PBMC IN VITRO AND IN AN IN VIVO T CELL TRANSFER MODEL OF CHRONIC INFLAMMATORY BOWEL DISEASE (IBD) Inflammatory Bowel Diseases ·Kristine M. Swiderek,Stacey R. Dillon,John W. Moore,Susan Bort,Sherri Mudri,Deniz Gediz,Mark W. Rixon,Janhavi Bhandari,Stanford L. Peng	2020	1
7	Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding Proceedings of the National Academy of Sciences ·Jinghua Lu,紫乃西沢,Zhongcheng Zou,Nels Hamacher,Mark W. Rixon,Peter D. Sun	2015	121
8	Generation and characterization of human anti-human IL-21 neutralizing monoclonal antibodies mAbs ·Mark Maurer,Ursula Garrigues,Stephen R. Jaspers,Brent Meengs,Mark W. Rixon,孙颢洋 SUN Haoyang,Kenneth B. Lewis,Georsios I. Angelis,Thomas R. Bukowski,Anitra C. Wolf,Nels Hamacher,Nadja Cristiane Lappann Bott,Stacey R. Dillon	2012	12
9	Generation of a high-affinity Fc receptor by Ig-domain swapping between human CD64A and CD16A Protein Engineering Design and Selection ·Jeff L. Ellsworth,Nels Hamacher,Brandon Harder,Mark Maurer,Thomas R. Bukowski,Stela Horvat,Lingling Ge,Mark W. Rixon,Brian A. Fox,Keir Lewis,Brent Meengs,А. Д. Молчанов,K. Greeff,К.В. Сыроквашина,Carl Birks	2010	5
10	Recombinant Soluble Human FcγR1A (CD64A) Reduces Inflammation in Murine Collagen-Induced Arthritis The Journal of Immunology ·Jeff L. Ellsworth,Nels Hamacher,Brandon Harder,Fares ElSalamony,Thomas R. Bukowski,Kelly Byrnes-Blake,S.J. Eskens,Colleen Oliver,Kimberly S. Waggie,和宏木原,Mark Shilling,Mark W. Rixon,Katherine E. Lewis	2009	25
11	TACI‐Ig prevents the development of airway hyperresponsiveness in a murine model of asthma Clinical & Experimental Allergy ·Janine Bilsborough,Ellen G. Chadwick,Sherri Mudri,Nancy Cline,William R. Henderson,Kimberly S. Waggie,Mark Shilling,Gerasimos Hatzidamianos,Mark W. Rixon,Jane A. Gross,Stacey R. Dillon	2008	13
12	TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Diseasebreakdown → Immunity ·Jane A. Gross,Stacey R. Dillon,Sherri Mudri,Janet Johnston,Αγγελική Καρασιώτου,C. K. SWARTZ,Mark W. Rixon,Ole Schou,Kevin P. Foley,Harald S. Haugen,Susan McMillen,Kim Waggie,C. W. Kesson,I Maznas,Gulchekhra Shavkatovna Rikhsieva,Margaret Moore,Maria Spyridopoulou,A Harvie	2001	509
13	Cloning and gene expression of a novel human ribonucleoprotein Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression ·Darrell Conklin,Mark W. Rixon,Rolf Kuestner,Mark Maurer,Theodore E. Whitmore,Robert P. Millar	2000	22
14	Preferential use of a H chain V region in antitumor-associated glycoprotein-72 monoclonal antibodies. The Journal of Immunology ·Mark W. Rixon,Brian B. Gourlie,D A Kaplan,Jeffrey Schlom,Peter Mézeš	1993	11
15	Expression of the human .gamma.-globin gene after retroviral transfer to transformed erythroid cells Biochemistry ·Mark W. Rixon,Edith A. S. Harris,Richard Gelinas	1990	11
16	A Fetal Globin Gene Mutation in ^Aϒ Nondeletion Hereditary Persistence of Fetal Hemoglobin Increases Promoter Strength in a Nonerythroid Cell Molecular and Cellular Biology ·Mark W. Rixon,Richard Gelinas	1988	6
17	A fetal globin gene mutation in A gamma nondeletion hereditary persistence of fetal hemoglobin increases promoter strength in a nonerythroid cell. Molecular and Cellular Biology ·Mark W. Rixon,Richard Gelinas	1988	34
18	Characterization of a complementary deoxyribonucleic acid coding for the .alpha. chain of human fibrinogen Biochemistry ·Mark W. Rixon,Wai‐Yee Chan,Earl W. Davie,Dominic W. Chung	1983	70
19	CLONING OF FIBRINOGEN GENES AND THEIR cDNA* Annals of the New York Academy of Sciences ·Dominic W. Chung,Mark W. Rixon,Benito G. Que,Earl W. Davie	1983	20
20	Characterization of a cDNA clone coding for the beta chain of bovine fibrinogen. Proceedings of the National Academy of Sciences ·Dominic W. Chung,Mark W. Rixon,Ross T. A. MacGillivray,Earl W. Davie	1981	41

About Mark W. Rixon

Mark W. Rixon is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging, Genetics, Hematology and Immunology and Allergy, having authored 25 papers that have together received 1.1k indexed citations. Recurring topics across this work include T-cell and B-cell Immunology (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Immune Cell Function and Interaction (7 papers), Blood properties and coagulation (4 papers), Glycosylation and Glycoproteins Research (3 papers), Immunodeficiency and Autoimmune Disorders (3 papers), RNA modifications and cancer (3 papers) and Hemoglobinopathies and Related Disorders (3 papers). The work is most often cited by research in Immunology (566 citations), Radiology, Nuclear Medicine and Imaging (289 citations), Immunology and Allergy (66 citations), Hematology (117 citations) and Genetics (106 citations). Mark W. Rixon has collaborated with scholars based in United States, Germany and South Africa. Frequent co-authors include Dominic W. Chung, Earl W. Davie, Stacey R. Dillon, Sherri Mudri, Jane A. Gross, Harald S. Haugen, Susan McMillen, Kim Waggie, Kevin P. Foley and Margaret Moore. Their work appears in journals such as Biochemistry, The Journal of Immunology, Proceedings of the National Academy of Sciences, Molecular and Cellular Biology and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact